PIM kinases have also been identified as mediators of drug resistance in other contexts [58], including resistance to MET inhibitors in lung or gastric cancers [59, 60], suggesting the application of PIM inhibition to other therapeutic combinations in additional tumor indications. This evidence concerns the gene MET and gastric cancer.